Most Read Articles
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 5 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.

Comorbidities, disease severity predict death in hospitalized asthma patients

18 Apr 2020

The risk of death in patients hospitalized for asthma exacerbation is associated with specific comorbidities, disease severity, and prescription patterns of short-acting β2-agonist (SABA), oral (OCS) and inhaled corticosteroids (ICS), according to a study.

The analysis involved 267 patients who died after asthma admission and 1,035 controls who were discharged after admission. The median age of the overall population was 77 years, and 50.7 percent of the patients were female. The mean duration of follow-up was 3 years.

In multivariable conditional logistic regression models, independent risk factors for death included comorbidities of pneumonia (adjusted odds ratio [aOR], 3.82, 95 percent confidence interval [CI], 2.41–6.05), genitourinary disease (aOR, 1.75, 95 percent CI, 1.17–2.62), septicemia (aOR, 4.26, 95 percent CI, 2.61–6.94), diabetes mellitus (aOR, 2.10, 95 percent CI, 1.30–3.38), arrhythmia (aOR, 2.00, 95 percent CI, 1.14–3.50), and a history of asthmatic hospitalization (aOR, 4.48, 95 percent CI, 2.77–7.25).

The risk of death also increased with the use of SABA and OCS use at >70 mg prednisolone during previous hospitalization (p<0.05) and OCS use at ≥110 mg prednisolone/month during outpatient treatment (aOR, 2.21, 95 percent CI, 1.08–4.50).

On the other hand, ICS use of ≥4 canisters/year conferred a survival benefit (aOR, 0.39, 95 percent CI, 0.19–0.78).

The present data may aid in identifying asthmatic patients who are at a higher mortality risk as well as refining the management of the condition, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 5 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.